Table 2. The molecular function of MDS-related patients with GO analysis.
| Term description | Observed gene count | FDR | Matching proteins in your network (labels) |
|---|---|---|---|
| The molecular function of MDS patients with GO analysis | |||
| Organic cyclic compound binding | 17 | 5.4E–07 | ASXL1, CEBPA, DNMT3A, ETV6, IDH1, IDH2, KRAS, NPM1, NRAS, PHF6, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, ZRSR2 |
| Heterocyclic compound binding | 17 | 5.4E-07 | ASXL1, CEBPA, DNMT3A, ETV6, IDH1, IDH2, KRAS, NPM1, NRAS, PHF6, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, ZRSR2 |
| Nucleic acid binding | 13 | 1.69E–05 | ASXL1, CEBPA, DNMT3A, ETV6, NPM1, PHF6, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, ZRSR2 |
| Transcription regulator activity | 11 | 1.69E–05 | ASXL1, CBL, CEBPA, DNMT3A, ETV6, NPM1, PHF6, RUNX1, SETBP1, SRSF2, TP53 |
| Isocitrate dehydrogenase (NADP+) activity | 2 | 0.00016 | IDH1, IDH2 |
| DNA binding | 10 | 0.00047 | ASXL1, CEBPA, DNMT3A, ETV6, NPM1, PHF6, RUNX1, SETBP1, TET2, TP53 |
| DNA-binding transcription factor activity | 8 | 0.0017 | CBL, CEBPA, DNMT3A, ETV6, PHF6, RUNX1, SETBP1, TP53 |
| Binding | 18 | 0.0024 | ASXL1, CBL, CEBPA, DNMT3A, ETV6, IDH1, IDH2, KRAS, NPM1, NRAS, PHF6, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, ZRSR2 |
| Transcription factor binding | 5 | 0.0031 | ASXL1, CEBPA, NPM1, RUNX1, TP53 |
| Kinase binding | 5 | 0.0046 | CBL, CEBPA, NPM1, SRSF2, TP53 |
| The molecular function of suspected MDS patients with GO analysis | |||
| Nucleic acid binding | 8 | 0.00087 | ASXL1, DNMT3A, PHF6, RUNX1, SRSF2, TET2, TP53, U2AFBP |
| Metal ion binding | 9 | 0.00087 | ASXL1, CBL, DNMT3A, IDH1, PHF6, RUNX1, TET2, TP53, U2AFBP |
| Transcription regulator activity | 7 | 0.00087 | ASXL1, CBL, DNMT3A, PHF6, RUNX1, SRSF2, TP53 |
| Organic cyclic compound binding | 9 | 0.0017 | ASXL1, DNMT3A, IDH1, PHF6, RUNX1, SRSF2, TET2, TP53, U2AFBP |
| Heterocyclic compound binding | 9 | 0.0017 | ASXL1, DNMT3A, IDH1, PHF6, RUNX1, SRSF2, TET2, TP53, U2AFBP |
| Pre-mRNA binding | 2 | 0.0033 | SRSF2, U2AFBP |
| Receptor tyrosine kinase binding | 2 | 0.0073 | CBL, TP53 |
| DNA binding | 6 | 0.0074 | ASXL1, DNMT3A, PHF6, RUNX1, TET2, TP53 |
| Phosphoprotein binding | 2 | 0.0091 | CBL, PHF6 |
| DNA-binding transcription factor activity | 5 | 0.0107 | CBL, DNMT3A, PHF6, RUNX1, TP53 |
| The molecular function of MDS transformation-related patients with GO analysis | |||
| Nucleic acid binding | 7 | 0.0022 | ASXL1, CEBPA, DNMT3A, ETV6, RUNX1, SETBP1, U2AFBP |
| DNA binding | 6 | 0.0022 | ASXL1, CEBPA, DNMT3A, ETV6, RUNX1, SETBP1 |
| Organic cyclic compound binding | 8 | 0.0022 | ASXL1, CEBPA, DNMT3A, ETV6, IDH2, RUNX1, SETBP1, U2AFBP |
| Transcription regulator activity | 6 | 0.0022 | ASXL1, CEBPA, DNMT3A, ETV6, RUNX1, SETBP1 |
| Heterocyclic compound binding | 8 | 0.0022 | ASXL1, CEBPA, DNMT3A, ETV6, IDH2, RUNX1, SETBP1, U2AFBP |
| DNA-binding transcription factor activity, RNA polymerase II-specific | 5 | 0.0024 | CEBPA, DNMT3A, ETV6, RUNX1, SETBP1 |
| DNA-binding transcription activator activity, RNA polymerase II-specific | 3 | 0.0046 | CEBPA, ETV6, RUNX1 |
| RNA polymerase II proximal promoter sequence-specific DNA binding | 3 | 0.0052 | CEBPA, ETV6, RUNX1 |
| Transcription factor binding | 3 | 0.0099 | ASXL1, CEBPA, RUNX1 |
| Transcription coactivator activity | 2 | 0.0255 | ASXL1, CEBPA |
MDS, myelodysplastic syndrome; GO, Gene Oncology; FDR, false discovery rate.